Eliquis (apixaban) is a prescription anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is one of the most widely prescribed anticoagulants, and is considered to be an effective and safe treatment option for many patients. However, there are potential risks associated with Eliquis, particularly in the elderly population. This article will discuss the potential risks of Eliquis in the elderly, including side effects, potential interactions with other medications, and the importance of monitoring for adverse reactions.
Eliquis is a direct factor Xa inhibitor, which works by blocking the action of factor Xa, a protein involved in the clotting process. This helps to prevent the formation of blood clots, which can cause serious health problems such as stroke, heart attack, and pulmonary embolism. Eliquis is generally well-tolerated, but it is important to be aware of the potential risks associated with taking this medication.
The elderly population is particularly vulnerable to the side effects of Eliquis. Common side effects of Eliquis include nausea, headache, dizziness, and fatigue. Elderly patients may also be more likely to experience bleeding, including bleeding from the nose, gums, or rectum, as well as bruising more easily. In some cases, Eliquis can also cause anemia, which can lead to fatigue and shortness of breath.
Eliquis can interact with other medications, including non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and other anticoagulants. It is important to discuss all medications that a patient is taking with their doctor, as some medications may increase the risk of bleeding or other side effects when taken with Eliquis.
It is important for elderly patients taking Eliquis to be monitored closely for any adverse reactions, such as bleeding or bruising. Patients should also be aware of the signs and symptoms of anemia, such as fatigue and shortness of breath. Regular blood tests should be done to monitor for any changes in the blood.
Eliquis is a widely prescribed anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. While Eliquis is generally well-tolerated, there are potential risks associated with taking this medication, particularly in the elderly population. It is important to be aware of the potential side effects of Eliquis, as well as any potential interactions with other medications. Regular monitoring for adverse reactions is also important, as this can help to detect any problems early and reduce the risk of serious complications.
1.
Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.
2.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
3.
Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.
4.
A garden can save your life
5.
Effective Intralesional Melanoma Therapy May Involve Systemic Effects.
1.
Precision Oncology Advances: Neoantigen Therapies, TCR Strategies & Radiotherapy Innovations
2.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
3.
Building Physical Resilience in Chronic Blood Disorders
4.
Advanced Approaches in Oncology and Patient Outcomes
5.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Common side effects of cancer treatment and how they are managed
2.
Case-Based Learning: Oncology
3.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
4.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
5.
Understanding the Importance of Follow-Up After Cancer Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation